Paz-Ares's Lab

1.6K posts

Paz-Ares's Lab banner
Paz-Ares's Lab

Paz-Ares's Lab

@PazAresLab

Research group @CNIOStopCancer and H12O led by @LuisPaz_Ares. Exploring new therapies for lung cancer. Tweets by Itziar Otano

Madrid Katılım Ekim 2021
757 Takip Edilen1.1K Takipçiler
Paz-Ares's Lab retweetledi
Nature Rev Immunol
Nature Rev Immunol@NatRevImmunol·
New insights into progenitor exhausted T cell populations dlvr.it/TTH8HV
English
1
34
115
9.4K
Paz-Ares's Lab retweetledi
SOSCLC_AECC
SOSCLC_AECC@SOSCLC_AECC·
💚 Día Mundial Sin Tabaco 💚 Cambia el humo por aire. Dejar de fumar, o no empezar nunca, es uno de los mayores regalos para nuestra salud y nuestros pulmones. Desde SOSCLC-AECC seguimos impulsando la investigación, la prevención y la concienciación frente al cáncer de pulmón.💚
SOSCLC_AECC tweet mediaSOSCLC_AECC tweet mediaSOSCLC_AECC tweet mediaSOSCLC_AECC tweet media
Español
0
2
3
111
Paz-Ares's Lab retweetledi
SOSCLC_AECC
SOSCLC_AECC@SOSCLC_AECC·
Celebrado el III Strategic Scientific Committee Meeting de SOSCLC-AECC en el Hospital 12 de Octubre. Investigadores e IPs de todos los Work Packages se reunieron presencialmente y online para compartir avances y seguir impulsando la investigación en cáncer de pulmón microcítico.
SOSCLC_AECC tweet media
Español
0
4
7
674
Paz-Ares's Lab retweetledi
Abner Antonio Murray, MD PhD
Abner Antonio Murray, MD PhD@dominicandoc2·
Excellent translational work from @BrunaPellini et al. 🔑: resistance after #KRAS #G12C inhibition may create new therapeutic vulnerabilities rather than simply closing doors. 🚪 ‼️ Implications for #ADC combinations, #HER2 assessment in #NSCLC, and post-KRAS inhibitor treatment strategies. Worth reading. 📖 🤔Could adaptive HER2 upregulation become a clinically useful biomarker, or is HER2 scoring in #lungcancer still too variable? 🧬 🫁 @KRASKickers @Exon20Group @LUNGevity #LCSM #KRASG12C @ChristianRolfo
Bruna Pellini, MD@BrunaPellini

🚨New Pub 🧵1) Our new study in #TranslationalLungCancerResearch explores a combination strategy for #KRASG12C-mutant #NSCLC: sotorasib plus trastuzumab deruxtecan. In preclinical models, the combination produced deeper and more durable regressions than either agent alone. tlcr.amegroups.org/article/view/1…

English
0
7
12
2.4K
Paz-Ares's Lab retweetledi
Klebanoff_Lab
Klebanoff_Lab@KlebanoffLab·
👉Clinical validation that T stem cell (TSCM) memory CD8+ T cells mediate superior persistence and antitumor immunity following adoptive transfer. Congrats to Gattinoni et al. for bringing this seminal discovery full circle🧬! @uni_regensburg dlvr.it/TSJdp5
English
0
10
61
2.8K
Paz-Ares's Lab retweetledi
Hospital Universitario 12 de Octubre
♋ Si eres paciente de cáncer o familiar y quieres saber cómo se impulsa, organiza y valora la investigación clínica en oncología, quizás te interese: ✅ #H12O y AECC te invitan a un encuentro con investigadores. 🗓️ 26 Mayo. 11-14h. #somosdel12c.madrid/2sgh61
Hospital Universitario 12 de Octubre tweet media
Español
0
15
17
1.3K
Paz-Ares's Lab retweetledi
Garcia-Carbonero's Lab
Garcia-Carbonero's Lab@GCarboneroLab·
🚨 #Hiring: Staff Scientist/Postdoc (Non-PI) – Madrid 🇪🇸 Translational oncology: tumor biology, biomarkers & precision medicine. PhD + experience in molecular biology & preclinical models required. 👉 Apply bsoldevilla.imas12@h12o.es rolinferrer.imas12@h12o.es
Garcia-Carbonero's Lab tweet mediaGarcia-Carbonero's Lab tweet media
English
0
5
6
722
Paz-Ares's Lab retweetledi
ACIR
ACIR@ACIR_org·
Based on the randomized phase 3 LungTIME-C01 trial, Huang et al. reported that early time of day (ToD) treatment (before 3 pm) for the first 4 doses improved anti-PD-1 efficacy compared with late ToD treatment (after 3 pm) in patients with stage IIIC–IV NSCLC. For the early ToD group, median PFS and OS were 11.3 and 28.0 months, compared to the late ToD group, which were 5.7 and 16.8 months, respectively. Between both groups, no differences in incidence of immune-related adverse events were observed. Circulating CD8+ T cells increased in the early ToD group, with a higher activated (CD38+ HLA-DR+) versus exhausted (TIM-3+PD-1+) ratio. bit.ly/4rWdKfB
ACIR tweet media
English
0
4
4
539
Paz-Ares's Lab retweetledi
Global Immunotalks
Global Immunotalks@globalimmuno·
Global Immunotalks 2026 has just begun!
Global Immunotalks tweet media
English
0
2
23
2.6K
Paz-Ares's Lab retweetledi
Global Immunotalks
Global Immunotalks@globalimmuno·
2026 is here! We’re excited to share Global Immunotalks first semester poster, featuring an outstanding lineup! Please share and help us spread the word!
Global Immunotalks tweet media
English
0
11
21
1.4K
Paz-Ares's Lab retweetledi
Nature Rev Immunol
Nature Rev Immunol@NatRevImmunol·
Inflame and restrain — the paradoxical roles of IL-12 and IL-23 in immunity dlvr.it/TQFz0q
English
2
26
122
7.6K